Table 1.
Summary of cost and benefits per individual aged >65 years in the population of HD-QIV versus aQIV: hospitalizations conditional on developing influenza.
| aQIV strategy | HD-QIV strategy | Incremental | ICER | |
|---|---|---|---|---|
| HD-QIV vs. aQIV (where relative efficacy of aQIV vs. SD-QIV assumed as 0%) | ||||
| Total costs | 15.44 € | 24.11 € | 8.67 € | – |
| Total LYs | 10.2447 | 10.2460 | 0.00131 | 6,605 € |
| Total QALYs | 8.8905 | 8.8917 | 0.00118 | 7,301 € |
| HD-QIV vs. aQIV (where relative efficacy of aQIV vs. SD-QIV assumed as 6%) | ||||
| Total costs | 15.35 € | 24.11 € | 8.76 € | – |
| Total LYs | 10.2450 | 10.2460 | 0.00099 | 8,870 € |
| Total QALYs | 8.8908 | 8.8917 | 0.00089 | 9,805 € |
| HD-QIV vs. aQIV (where relative efficacy of aQIV vs. SD-QIV assumed as 12%) | ||||
| Total costs | 15.27 € | 24.11 € | 8.84 € | – |
| Total LYs | 10.2453 | 10.2460 | 0.00066 | 13,364 € |
| Total QALYs | 8.8911 | 8.8917 | 0.00059 | 14,733 € |